Catalyst
Monitor trial enrollment and results, particularly the efficacy of rivaroxaban in preventing strokes in patients identified by left atrial strain metrics.
Date
June 14, 2026
Phase
N/A
Status
watch
Signal score
8.0
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.